Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 1/2018

01-01-2018 | Review – Clinical Oncology

Cardiovascular effects of Hodgkin’s lymphoma: a review of literature

Authors: Aasems Jacob, Bragadheeswar Thyagarajan, Monisha Priyadarshini Kumar, Nasreen Shaikh, David Sharon

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2018

Login to get access

Abstract

Hodgkin’s lymphoma (HL) constitutes 0.6% of all the cancers diagnosed worldwide and 10% of all lymphomas. Ten-year survival rate for HL is estimated to be 80% and cardiovascular death is the prevalent cause for a non-malignant death among these HL survivors. We are reviewing the cardiovascular morbidities associated with Hodgkin’s lymphoma from the available literature. We performed a systematic review of all articles published from January 1, 1960 to October 1, 2016 on the MEDLINE database using PubMed search engine. Key factors in the diagnosis and management of these conditions are discussed in individual sections.
Literature
Adams MJ, Lipsitz SR, Colan SD et al (2004) Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 22:3139CrossRefPubMed
Adler Y, Charron P, Imazio M et al (2015) European Society of Cardiology (ESC) 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36(42):2921–2964CrossRefPubMed
Akhter MW, Aronson D, Bitar F, Khan S, Singh H et al (2004) Effect of elevated admission serum creatinine and its worsening on outcome in hospitalised patients with decompensated heart failure. Am J Cardiol 94:957–960CrossRefPubMed
Aleman BM, van den Belt-Dusebout AW, Klokman WJ et al (2003) Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21:3431–3439CrossRefPubMed
Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109(5):1878–1886CrossRefPubMed
Al-Kindi SG, Abu-Zeinah GF, Kim CH, Hejjaji V, William BM, Caimi PF, Oliveira GH (2015) Trends and disparities in cardiovascular mortality among survivors of Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 15(12):748–752CrossRefPubMed
Armenian SH, Xu L, Ky B et al (2016) Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. J Clin Oncol 34:1122–1130CrossRefPubMed
Bashir H, Hudson MM, Kaste SC, Howard SC, Krasin M, Metzger ML (2007) Pericardial involvement at diagnosis in pediatric Hodgkin lymphoma patients. Pediatr Blood Cancer 49(5):666–671CrossRefPubMed
Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). J Am Coll Cardiol 61:2355–2362CrossRefPubMed
Brand MD, Abadi CA, Aurigemma GP, Dauerman HL, Meyer TE (2001) Radiation-associated valvular heart disease in Hodgkin’s disease is associated with characteristic thickening and fibrosis of the aortic-mitral curtain. J Heart Valve Dis 10(5):681–685PubMed
Cagdas M, Velibey Y, Calik AN, Satilmis S (2012) An incidentally detected paraaortic mass diagnosed as bulky disease. Turk Kardiyol Dern Ars 40(2):197CrossRefPubMed
Cavill I, Auerbach M, Bailie GR, Barrett-Lee P, Beguin Y, Kaltwasser P, Littlewood T, Macdougall IC, Wilson K (2006) Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 22(4):731–737CrossRefPubMed
Cella L, Liuzzi R, Conson M et al (2011) Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin’s lymphoma. Radiother Oncol 101(2):316–321CrossRefPubMed
Chen AB, Punglia RS, Kuntz KM et al (2009) Cost effectiveness and screening interval of lipid screening in Hodgkin’s lymphoma survivors. J Clin Oncol 27:5383CrossRefPubMedPubMedCentral
Chiles C, Woodard PK, Gutierrez FR, Link KM (2001) Metastatic involvement of the heart and pericardium: CT and MR imaging. Radiographics 21:439–449CrossRefPubMed
Crowe JE (1975) Cardiophrenic adenopathy in Hodgkin disease. Am J Dis Child 129(1):116–117PubMed
Dawson WB, Mayo JR, Muller NL (1990) Computed tomography of cardiac and pericardial tumors. Can Assoc Radiol J 41:270–275PubMed
De Bruin ML, Dorresteijn LD, van’t Veer MB et al (2009) Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 101:928CrossRefPubMed
Diehl LF, Hopper KD, Giguere J, Granger E, Lesar M (1991) The pattern of intrathoracic Hodgkin’s disease assessed by computed tomography. J Clin Oncol 9:438–443CrossRefPubMed
Diehl V, Thomas RK, Re D (2004) Part II: Hodgkin’s lymphoma—diagnosis and treatment. Lancet Oncol 5:19–26CrossRefPubMed
Dubrey SW, Hawkins PN, Falk RH (2011) Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart [British Cardiac Society] 97(1):75–84CrossRef
Engert A, Josting A, Haverkamp H et al (2010) Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 28(13):2239–2245CrossRefPubMed
Ewing DJ, Martyn CN, Young RJ et al (1985) The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 8:491–498CrossRefPubMed
Georgakopoulos P, Roussou P, Matsakas E et al (2010) Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol 2010 85:894CrossRefPubMed
Groarke JD, Tanguturi VK, Hainer J et al (2015) Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol 65:573CrossRefPubMed
Gulati G, Heck SL, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37:1671CrossRefPubMedPubMedCentral
Hadar A, Sheiner E, Press F, Katz A, Katz M (2004) Dilated cardiomyopathy in a pregnant woman after doxorubicin and radiotherapy for Hodgkin’s disease: a case report. J Reprod Med 49(5):401–403PubMed
Hancock SL, Hoppe RT (1996) Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 6:225–242CrossRefPubMed
Hasan S, Dinh K, Lombardo F et al (2004) Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc 96(2):196–199PubMedPubMedCentral
Heidenreich PA, Hancock SL, Vagelos RH et al (2005) Diastolic dysfunction after mediastinal irradiation. Am Heart J 150:977CrossRefPubMed
Heidenreich PA, Schnittger I, Strauss HW et al (2007) Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 25:43CrossRefPubMed
Hering D, Faber L, Horstkotte D (2003) Echocardiographic features of radiation-associated valvular disease. Am J Cardiol 92(2):226–230CrossRefPubMed
Janeczek M, Bąkała W (2012) Acquired pulmonary stenosis due to Hodgkin’s lymphoma. Kardiol Pol 70(5):527–528 (Polish)PubMed
Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258CrossRefPubMed
Kaya MG, Ozkan M, Gunebakmaz O et al (2013) Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol 167:2306CrossRefPubMed
Keelan MH Jr, Rudders RA (1974) Successful treatment of radiation pericarditis with corticosteroids. Arch Intern Med 134(1):145–147CrossRefPubMed
Korecki J, Kamiński KA, Lisowska A, Musiał WJ (2005) Supraventricular tachycardia and pulmonary hypertension at the presentation of Hodgkin’s disease. Acta Cardiol 60(6):655–657CrossRefPubMed
Larsen RL, Jakacki RI, Vetter VL et al (1992) Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 70:73CrossRefPubMed
Larsson O, Stein G, Seivers J (1976) Hodgkin’s disease presenting as pericarditis. Med J Aust 2(7):254–255PubMed
Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351:145–153CrossRefPubMed
Lotrionte M, Palazzoni G, Abbate A et al (2013) Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (liposomal doxorubicin–investigational chemotherapy–tissue doppler imaging evaluation) randomized pilot study. Int J Cardiol 167:1055–1057CrossRefPubMed
Machann W, Beer M, Breunig M et al (2010) Cardiac magnetic resonance imaging findings in 20-year survivors of mediastinal radiotherapy for Hodgkin’s disease. Int J Radiat Oncol Biol Phys 79(4):1117–1123CrossRefPubMed
Maher EA, Shepherd FA, Todd TJ (1996) Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg 112:637–643CrossRefPubMed
Maraldo MV, Aznar MC, Vogelius IR, Petersen PM, Specht L (2013) Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 85(4):1057–1065CrossRefPubMed
Marks RD Jr, Agarwal SK, Constable WC (1973) Radiation induced pericarditis in Hodgkin’s disease. Acta Radiol Ther Phys Biol 12(4):305 – 12CrossRefPubMed
Meng Q, Lai H, Lima J et al (2002) Echocardiographic and pathological characteristics of cardiac metastasis in patients with lymphoma. Oncol Rep 9:85–88PubMed
Millaire A, Wurtz A de GP et al (1992) Malignant pericardial effusions: usefulness of pericardioscopy. Am Heart J 124:1030–1034CrossRefPubMed
Ng AK, Bernardo MP, Weller E et al (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20:2101–2108CrossRefPubMed
Petersen CD, Robinson WA, Kurnick JE (1976) Involvement of the heart and pericardium in the malignant lymphomas. Am J Med Sci 272:161–165CrossRefPubMed
Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25(25):3808–3815CrossRefPubMed
Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28(33):4996–5010CrossRefPubMed
Roberts WC, Glancy DL, DeVita VT Jr (1968) Heart in malignant lymphoma [Hodgkin’s disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides]. A study of 196 autopsy cases. Am J Cardiol 22:85–107CrossRefPubMed
Ruhl U, Albrecht M, Dieckmann K et al (2001) Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 51:1209–1218CrossRefPubMed
Santoro A, Bonadonna G, Valagussa P et al (1987) Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27CrossRefPubMed
Schachter S, Freeman R (1982) Transient ischemic attack and adriamycin cardiomyopathy. Neurology 32(12):1380–1381CrossRefPubMed
Schoen FJ, Berger BM, Guerina NG (1984) Cardiac effects of noncardiac neoplasms. Cardiol Clin 2:657–670PubMed
Serrano C, Cortés J, De Mattos-Arruda L et al (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 23:897–902CrossRefPubMed
Specht L, Yahalom J, Illidge T et al (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862CrossRefPubMed
Swerdlow AJ, Higgins CD, Smith P et al (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206–214CrossRefPubMed
Talreja DR, Edwards WD, Danielson GK et al (2003) Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation 108:1852CrossRefPubMed
Tirelli U, Errante D, Van Glabbeke M et al (1998) CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin’s lymphoma. results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16(1):27–34CrossRefPubMed
Turner ML, Boland OM, Parker AC, Ewing DJ (1993) Subclinical autonomic dysfunction in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Br J Haematol 84(4):623–626CrossRefPubMed
van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 175(6):1007–1017CrossRefPubMed
van Dalen EC, van der Pal HJ, Kremer LC (2016) Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 3:CD005008PubMed
van Nimwegen FA, Schaapveld M, Cutter DJ et al (2016) Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 34:235–243CrossRefPubMed
Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 27:766–773CrossRefPubMed
Xiros N, Binder T, Anger B, Böhlke J, Heimpel H (1988) Idiopathic thrombocytopenic purpura and Autoimmune hemolytic anemia in Hodgkin’s disease. Eur J Haematol 40:437–441CrossRefPubMed
Zubrikhina GN, Blindar VN, Matveeva II, Demina EA (2015) The characteristics of anemic syndrome in patients with prevalent phases of Hodgkin lymphoma before treatment. Klin Lab Diagn 60(2):28–32 (Russian)PubMed
Metadata
Title
Cardiovascular effects of Hodgkin’s lymphoma: a review of literature
Authors
Aasems Jacob
Bragadheeswar Thyagarajan
Monisha Priyadarshini Kumar
Nasreen Shaikh
David Sharon
Publication date
01-01-2018
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2018
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2560-x

Other articles of this Issue 1/2018

Journal of Cancer Research and Clinical Oncology 1/2018 Go to the issue

Review – Cancer Research

High-intensity exercise interventions in cancer survivors: a systematic review exploring the impact on health outcomes

Original Article – Cancer Research

Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck

Original Article – Clinical Oncology

Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database

Original Article – Cancer Research

Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells

Correction

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase

Original Article – Cancer Research

A revision of the Tokuhashi revised score improves the prognostic ability in patients with metastatic spinal cord compression
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits